MedTrace Logo

Evaluation of the HekaHeart Platform in Medication Management for Heart Failure Patients

NCT06433687 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2025-08-17

No results posted yet for this study

Summary

This pilot study will test the feasibility of a novel digital health technology-enabled platform, HekaHeart, developed to facilitate comprehensive medical management, including medication initiation, titration, e-prescription eligibility, remote patient monitoring, and communication of care coordination activities, for patients with Heart Failure with Reduced Ejection Fraction (HFrEF) not currently on all four pillars of guideline-directed medical therapy (GDMT).

Conditions

  • Heart Failure With Reduced Ejection Fraction

Interventions

DEVICE

HekaHeart platform medication management and remote monitoring

Onboarding to the HekaHeart platform which includes a personalized GDMT management plan along with remote monitoring kits including a scale, blood pressure cuff, and heart rate monitor. Patients engage in video and phone calls with clinicians who will use established standardized clinical protocols to guide medication and vital optimization. Once patients are determined to be maximally titrated on all GDMT, they are transitioned back to standard clinical care.

Sponsors & Collaborators

  • HekaHeart

    collaborator UNKNOWN

  • Yale University

    lead OTHER

Principal Investigators

  • Francis P Wilson, MD MSCE · Yale University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-31
Primary Completion
2026-10-31
Completion
2026-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06433687 on ClinicalTrials.gov